CYTOKERATIN IMMUNOREACTIVITY IN GLIOMAS
CYTOKERATIN IMMUNOREACTIVITY IN GLIOMAS
复制标题
DOI：
10.1111/j.1365-2559.1989.tb02164.x
复制
发表时间：
1989-04-01
期刊：
影响因子：
6.4
通讯作者：
LO, STH
中科院分区：
文献类型：
--
作者：
NG, HK;LO, STH
针对细胞角蛋白的单克隆抗体（AE1/3、CAM 5.2和PKK-1）和多克隆抗血清与一系列星形细胞瘤、少突胶质细胞瘤和室管膜瘤反应。12例多形性胶质母细胞瘤中有7例（58%），8例间变性星形细胞瘤中有5例（63%），5例分化良好的星形细胞瘤中有2例（40%）对AE1/3有免疫反应，但对其他抗细胞角蛋白抗体无反应。在少突胶质细胞瘤中，AE1/3染色分离的星形细胞样细胞和分散的肿瘤少突胶质细胞在8例病例中有4例（50%）。4例室管膜瘤的所有细胞角蛋白标志物检测均为阴性。星形细胞瘤和少突胶质胶质瘤的AE1/3免疫染色可能代表胶质瘤中细胞角蛋白和胶质纤维酸性蛋白的共同表达，因此在胶质瘤和癌的鉴别诊断中应谨慎使用这些抗体。
Monoclonal antibodies (AE1/3, CAM 5.2 and PKK-1) and polyclonal antisera against the cytokeratin proteins were reacted with a range of astrocytic tumours, oligodendrogliomas and ependymomas. Seven of 12 cases (58%) of glioblastoma multiforme, five of eight (63%) anaplastic astrocytomas and two of five (40%) well-differential astrocytomas were immunoreactive with AE1/3 but not with the other anti-cytokeratin antibodies. In oligodendrogliomas, AE1/3 stained isolated astrocyte-like cells as well as scattered neoplastic oligodendrocytes in four of eight cases (50%) cases. Four ependymomas were negative for all cytokeratin markers examined. The immunostaining of astrocytomas and oligodendrogliomas with AE1/3 might represent co-expression of cytokeratin with glial fibrillary acidic protein by gliomas and calls for caution in the use of these antibodies in the differential diagnosis between gliomas and carcinomas.